Category: 64-10-8

In 2019.0 MOL CANCER THER published article about ACQUIRED-RESISTANCE; CAPRI-GOIM; PLUS CETUXIMAB; INHIBITOR; MUTATIONS in [Martini, Giulia; Cardone, Claudia; Vitiello, Pietro Paolo; Belli, Valentina; Napolitano, Stefania; Troiani, Teresa; Ciardiello, Davide; Della Corte, Carminia Maria; Morgillo, Floriana; Matrone, Nunzia; Ciardiello, Fortunato; Martinelli, Erika] Univ Campania L Vanvitelli, Med Oncol, Dept Precis Med, Via Pansini 5, I-80131 Naples, Italy; [Sforza, Vincenzo] Fdn Pascale, IRCCS, Ist Nazl Tumori, Dept Clin Expt Thorac Oncol, Naples, Italy; [Papaccio, Gianpaolo; Desiderio, Vincenzo; Tirino, Virginia] Univ Campania Luigi Vanvitelli Napoli, Dept Expt Med, Naples, Italy; [Paul, Mariel C.; Moreno-Viedma, Veronica; Sibilia, Maria] Med Univ Vienna, Comprehens Canc Ctr, Dept Med 1, Inst Canc Res, Borschkegasse 8a, Vienna, Austria; [Normanno, Nicola; Rachiglio, Anna Maria] Fdn Pascale, IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy; [Maiello, Evaristo; Latiano, Tiziana Pia; Rizzi, Daniele] Hosp Casa Sollievo Della Sofferenza San Giovanni, Med Oncol, San Giovanni Rotondo, Italy; [Signoriello, Giuseppe] Univ Campania L Vanvitelli, Biostat, Dipartimento Salute Mentale & Fis & Med Prevent, Naples, Italy in 2019.0, Cited 24.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. Safety of 1-Phenylurea

The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in colorectal cancer. We studied activation of EPHA2 in a panel of human colorectal cancer cell lines sensitive or resistant to anti-EGFR drugs. The in vitro and in vivo effects of ALW-II-41-27 (an EPHA2 inhibitor) and/or cetuximab treatment were tested. Fonnalin-fixed paraffin-embedded tumor specimens from 82 RAS wild-type (WV) metastatic colorectal cancer patients treated with FOLFIRI + cetuximab as first-line therapy in the CAPRI-COIM trial were assessed for EPHA2 expression by immunohistochemistry and correlated with treatment efficacy. EPHA2 was differentially activated in colorectal cancer cell lines. Combined treatment with ALW-II-41-27 plus cetuximab reverted primary and acquired resistance to cetuximab, causing cell growth inhibition, inducing apoptosis and cell-cycle G1-G2 arrest. In tumor xenograft models, upon progression to cetuximab, ALW-II-41-27 addition significantly inhibited tumor growth. EPHA2 protein expression was detected in 55 of 82 tumor samples, frequently expressed in less-differentiated and left-sided tumors. High levels of EPHA2 significantly correlated with worse progression-free survival [8.6 months; confidence interval (CI) 95%, 6.4-10.8; vs. 12.3 months; CI 95%, 10.4-14,2; P = 0.03] and with increased progression rate (29% vs. 9%, P = 0.02). A specific EPHA2 inhibitor reverts in vitro and in vivo primary and acquired resistance to anti-ECFR therapy. EPHA2 levels are significantly associated with worse outcome in patients treated with FOLFIRI + cetuximab. These results highlight EPHA2 as a potential therapeutic target in metastatic colorectal cancer.

About 1-Phenylurea, If you have any questions, you can contact Martini, G; Cardone, C; Vitiello, PP; Belli, V; Napolitano, S; Troiani, T; Ciardiello, D; Della Corte, CM; Morgillo, F; Matrone, N; Sforza, V; Papaccio, G; Desiderio, V; Paul, MC; Moreno-Viedma, V; Normanno, N; Rachiglio, AM; Tirino, V; Maiello, E; Latiano, TP; Rizzi, D; Signoriello, G; Sibilia, M; Ciardiello, F; Martinelli, E or concate me.. Safety of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

In 2019.0 LUNG CANCER published article about NSCLC; CHEMOTHERAPY; DOCETAXEL; SYSTEM in [Crino, Lucio; Bronte, Giuseppe; Cravero, Paola; Delmonte, Angelo] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy; [Bidoli, Paolo] Osped San Gerardo, Monza, Italy; [Minenza, Elisa] AO Santa Maria, Terni, Italy; [Cortesi, Enrico] Policlin Umberto 1, Rome, Italy; [Garassino, Marina C.; Proto, Claudia] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Cappuzzo, Federico] AUSL Romagna, Ravenna, Italy; [Grossi, Francesco] IRCCS AOU San Martino IST, Genoa, Italy; [Tonini, Giuseppe] Policlin Univ Campus Biomed, Rome, Italy; [Sarobba, Maria Giuseppina] ASL 3 S Francesco, Nuoro, Italy; [Pinotti, Graziella] Osped Circolo & Fdn Macchi, Varese, Italy; [Numico, Gianmauro] AO SS Antonio & Biagio & C Arrigo, Alessandria, Italy; [Samaritani, Riccardo] Presidio Nuovo Regina Margherita, Rome, Italy; [Ciuffreda, Libero] AOU Citta Salute & Sci Torino, Turin, Italy; [Frassoldati, Antonio] Arcispedale S Anna Ferrara, Ferrara, Italy; [Bregni, Marco] Presidio Osped Busto Arsizio, Varese, Italy; [Santo, Antonio] AO Univ Integrata Verona, Verona, Italy; [Piantedosi, Francovito; Illiano, Alfonso] AO Colli, Monaldi Cotugno CTO, Naples, Italy; [De Marinis, Filippo] European Inst Oncol, Milan, Italy; [Tamberi, Stefano] Infermi Hosp, Faenza, Italy; [Giannarelli, Diana] Regina Elena Natl Canc Inst IRCCS, Rome, Italy in 2019.0, Cited 22.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. Recommanded Product: 64-10-8

Objectives: Brain metastases are common among patients with non-squamous non-small-cell lung cancer (NSCLC) and result in a poor prognosis. Consequently, such patients are often excluded from clinical trials. In Italy an expanded access program (EAP) was used to evaluate nivolumab efficacy and safety in this sub population outside a clinical trial. Materials and methods: In this EAP, nivolumab was available for patients with non-squamous NSCLC in progression after at least one systemic treatment for stage IIIB/IV disease. Nivolumab 3 mg/kg was administered intravenously every 2 weeks. Patients with brain metastases could be included if they were asymptomatic, neurologically stable and either off corticosteroids or on a stable or decreasing dose of <= 10 mg/day prednisone. Results: 409 out of 1588 patients included had asymptomatic or controlled brain metastases. A median of 7 doses (range 1-45) were delivered. Median follow-up was 6.1 months (range 0.1-21.9). The disease control rate was 39%: 4 patients had a complete response, 64 a partial response and 96 showed stable disease. At baseline, 118 patients were on corticosteroids and 74 were undergoing concomitant radiotherapy. The median overall survival in this subpopulation was 8.6 months (95% CI: 6.4-10.8). 337 discontinued treatment for various reasons, 23 (7%) of whom due to adverse events, in line with that observed in the overall population and in previous studies. Conclusions: Our results confirm that nivolumab is active in non-squamous NSCLC patients with brain metastases, despite their poor prognosis. Its safety profile is also concordant with results in the EAP overall population and in patients with other malignancies. About 1-Phenylurea, If you have any questions, you can contact Crino, L; Bronte, G; Bidoli, P; Cravero, P; Minenza, E; Cortesi, E; Garassino, MC; Proto, C; Cappuzzo, F; Grossi, F; Tonini, G; Sarobba, MG; Pinotti, G; Numico, G; Samaritani, R; Ciuffreda, L; Frassoldati, A; Bregni, M; Santo, A; Piantedosi, F; Illiano, A; De Marinis, F; Tamberi, S; Giannarelli, D; Delmonte, A or concate me.. Recommanded Product: 64-10-8

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

An article Retarding frosting of an air source heat pump by using vapor-bypassed evaporation technique WOS:000662969100008 published article about DEFROSTING PERFORMANCE; CONDITIONING SYSTEM; EXCHANGER; UNIT in [Fan, Chaochao; Xiong, Tong; Yan, Gang; Yu, Jianlin; Zhang, Hao; Chu, Wenxiao; Wang, Qiuwang] Xi An Jiao Tong Univ, Dept Refrigerat & Cryogen Engn, Sch Energy & Power Engn, Xian 710049, Peoples R China; [Zhang, Hao] Guangdong Midea Refrigerat Equipment Co Ltd, Foshan 528311, Peoples R China in 2021.0, Cited 25.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. Recommanded Product: 64-10-8

This paper presents a comparative experimental study on the frosting characteristics of an air source heat pump system that contains two operation modes, i.e., the vapor-bypassed evaporation (VB) mode and the conventional operation (CO) mode. For VB mode, a phase separator is installed inside the evaporator re-frigerant circuit to bypass vapor refrigerant, which can increase the average evaporation temperature for retarding frosting by reducing refrigerant pressure drop and decreasing the area of refrigerant inferior heat transfer coefficient region (mist flow region). According to the experimental results, under H2 con-dition (indoor: 20/15 degrees C; outdoor: 2/1 degrees C), as the initial refrigerant mass flow rate ranges 35-45 g / s , the VB mode yields 4.30-7.06% lower frost mass, 3.9-7.3% higher average heating capacity and 6.4-10.8% higher coefficient of performance (COP) over CO mode with the frosting duration of 60 min. Moreover, under H3 condition (indoor: 20/15 degrees C; outdoor:-7/-8 degrees C), the frosting duration is set as 100 min, and the VB mode obtains 9.67% lower frost mass, 7.0% higher average heating capacity and 13.3% higher COP over CO mode. Generally, the vapor-bypassed evaporation technique has a great application potential in retarding frosting and improving performance of an air source heat pump system especially under high heating capacity or low ambient temperature conditions. (c) 2021 Elsevier Ltd and IIR. All rights reserved.

Recommanded Product: 64-10-8. About 1-Phenylurea, If you have any questions, you can contact Fan, CC; Xiong, T; Yan, G; Yu, JL; Zhang, H; Chu, WX; Wang, QW or concate me.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Authors Martini, G; Cardone, C; Vitiello, PP; Belli, V; Napolitano, S; Troiani, T; Ciardiello, D; Della Corte, CM; Morgillo, F; Matrone, N; Sforza, V; Papaccio, G; Desiderio, V; Paul, MC; Moreno-Viedma, V; Normanno, N; Rachiglio, AM; Tirino, V; Maiello, E; Latiano, TP; Rizzi, D; Signoriello, G; Sibilia, M; Ciardiello, F; Martinelli, E in AMER ASSOC CANCER RESEARCH published article about ACQUIRED-RESISTANCE; CAPRI-GOIM; PLUS CETUXIMAB; INHIBITOR; MUTATIONS in [Martini, Giulia; Cardone, Claudia; Vitiello, Pietro Paolo; Belli, Valentina; Napolitano, Stefania; Troiani, Teresa; Ciardiello, Davide; Della Corte, Carminia Maria; Morgillo, Floriana; Matrone, Nunzia; Ciardiello, Fortunato; Martinelli, Erika] Univ Campania L Vanvitelli, Med Oncol, Dept Precis Med, Via Pansini 5, I-80131 Naples, Italy; [Sforza, Vincenzo] Fdn Pascale, IRCCS, Ist Nazl Tumori, Dept Clin Expt Thorac Oncol, Naples, Italy; [Papaccio, Gianpaolo; Desiderio, Vincenzo; Tirino, Virginia] Univ Campania Luigi Vanvitelli Napoli, Dept Expt Med, Naples, Italy; [Paul, Mariel C.; Moreno-Viedma, Veronica; Sibilia, Maria] Med Univ Vienna, Comprehens Canc Ctr, Dept Med 1, Inst Canc Res, Borschkegasse 8a, Vienna, Austria; [Normanno, Nicola; Rachiglio, Anna Maria] Fdn Pascale, IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy; [Maiello, Evaristo; Latiano, Tiziana Pia; Rizzi, Daniele] Hosp Casa Sollievo Della Sofferenza San Giovanni, Med Oncol, San Giovanni Rotondo, Italy; [Signoriello, Giuseppe] Univ Campania L Vanvitelli, Biostat, Dipartimento Salute Mentale & Fis & Med Prevent, Naples, Italy in 2019.0, Cited 24.0. Application In Synthesis of 1-Phenylurea. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8

The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in colorectal cancer. We studied activation of EPHA2 in a panel of human colorectal cancer cell lines sensitive or resistant to anti-EGFR drugs. The in vitro and in vivo effects of ALW-II-41-27 (an EPHA2 inhibitor) and/or cetuximab treatment were tested. Fonnalin-fixed paraffin-embedded tumor specimens from 82 RAS wild-type (WV) metastatic colorectal cancer patients treated with FOLFIRI + cetuximab as first-line therapy in the CAPRI-COIM trial were assessed for EPHA2 expression by immunohistochemistry and correlated with treatment efficacy. EPHA2 was differentially activated in colorectal cancer cell lines. Combined treatment with ALW-II-41-27 plus cetuximab reverted primary and acquired resistance to cetuximab, causing cell growth inhibition, inducing apoptosis and cell-cycle G1-G2 arrest. In tumor xenograft models, upon progression to cetuximab, ALW-II-41-27 addition significantly inhibited tumor growth. EPHA2 protein expression was detected in 55 of 82 tumor samples, frequently expressed in less-differentiated and left-sided tumors. High levels of EPHA2 significantly correlated with worse progression-free survival [8.6 months; confidence interval (CI) 95%, 6.4-10.8; vs. 12.3 months; CI 95%, 10.4-14,2; P = 0.03] and with increased progression rate (29% vs. 9%, P = 0.02). A specific EPHA2 inhibitor reverts in vitro and in vivo primary and acquired resistance to anti-ECFR therapy. EPHA2 levels are significantly associated with worse outcome in patients treated with FOLFIRI + cetuximab. These results highlight EPHA2 as a potential therapeutic target in metastatic colorectal cancer.

About 1-Phenylurea, If you have any questions, you can contact Martini, G; Cardone, C; Vitiello, PP; Belli, V; Napolitano, S; Troiani, T; Ciardiello, D; Della Corte, CM; Morgillo, F; Matrone, N; Sforza, V; Papaccio, G; Desiderio, V; Paul, MC; Moreno-Viedma, V; Normanno, N; Rachiglio, AM; Tirino, V; Maiello, E; Latiano, TP; Rizzi, D; Signoriello, G; Sibilia, M; Ciardiello, F; Martinelli, E or concate me.. Application In Synthesis of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Product Details of 64-10-8. In 2021.0 SUGAR TECH published article about DEGRADATION; DIURON; HEXAZINONE; PESTICIDES; DISSIPATION; METRIBUZIN; FATE; VINASSE; CANE in [Viti, Marcela Lembi; dos Reis, Fabricia Cristina; Tornisielo, Valdemar Luiz] Univ Sao Paulo, Ctr Nucl Energy Agr, Piracicaba, SP, Brazil; [Mendes, Kassio Ferreira] Univ Fed Vicosa, Vicosa, MG, Brazil; [Dias Guimaraes, Ana Carolina] Univ Mato Grosso State, Alta Floresta, Mato Grosso, Brazil; [Martinez Soria, Maria Teresa] Univ La Rioja, Logrono, La Rioja, Spain in 2021.0, Cited 47.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8.

This study evaluated the remobilization, mineralization, and metabolism of herbicide-bound residues in soils amended with various types of sugarcane waste. Soil with bound residues of three herbicides and fresh soil samples were added to the biometric flasks, followed by the addition of vinasse, filter cake, or sugarcane straw in order to reactivate the microbial activity. In sandy loam soil, higher mineralization was observed where filter cake was added, and the maximum mineralized percentage was 7.7, 46.7, and 8.1% of diuron-, hexazinone-, and metribuzin-bound residues, respectively. Conversely, this soil presented a greater percentage of re-extractable hexazinone and metribuzin residues when vinasse was added. Among the examined herbicides, a higher percentage of bound metribuzin residues remained in the soil (57.5-75.6%). It was possible to identify both metabolites and parent compounds in the re-extracted residues, implying either species could bind to the soil. Therefore, this study has shown that bound residues of three herbicides and their metabolites can become bioavailable, and mineralized or returned to the soil solution, which could adversely affect subsequent crops or non-target organisms. Hence, the remobilization of bound residues must be taken into account when assessing the environmental risk of herbicides in soils in registration processes.

Product Details of 64-10-8. About 1-Phenylurea, If you have any questions, you can contact Viti, ML; Mendes, KF; dos Reis, FC; Guimaraes, ACD; Soria, MTM; Tornisielo, VL or concate me.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Recently I am researching about INTRAMUSCULAR INJECTIONS; LACTATIONAL PERFORMANCE; DIETARY-SUPPLEMENTS; METABOLISM; RESISTANCE; METHIONINE; ENERGY; MILK; FOLATE, Saw an article supported by the Agriculture et Agroalimentaire Canada (Ottawa, ON, Canada). Published in ELSEVIER SCIENCE INC in NEW YORK ,Authors: Girard, CL; Vanacker, N; Beaudet, V; Duplessis, M; Lacasse, P. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea. Quality Control of 1-Phenylurea

The present experiment was conducted to determine whether, during periods of negative energy balance, the increase in glucose availability, despite similar DMI and greater milk production, induced by a combined supplement of folic acid and vitamin B-12 was related to effects of insulin on metabolism. Sixteen multiparous Holstein cows averaging 45 days in milk (standard deviation: 3) were assigned to 8 blocks of 2 animals each according to their milk production (45 kg/d; standard deviation: 6) during the week preceding the beginning of the experiment. Within each block, they received weekly intramuscular injections of either saline (CON) or folic acid and vitamin B-12 (VIT) during 5 consecutive weeks. During the last week, the cows were fed 75% of their ad libitum intake during 4 d. Blood samples were taken the morning before starting the feed restriction and on the third day of feed restriction. On the fourth day of feed restriction, the daily meal was not served and an intravenous glucose tolerance test was performed. During the 4 wk preceding the feed restriction, milk production and DMI were not affected by treatments. During the feed restriction, the vitamin supplement tended to decrease milk fat concentration and increase milk concentration of lactose. Plasma concentrations of homocysteine, Ile, Leu, Val, and branched-chain AA increased in VIT cows during the restriction but not in CON cows. During the glucose tolerance test, insulin peak height was lower and insulin incremental positive area under the curve tended to be lower for VIT than for CON [83 (95% confidence interval, CI: 64-108) vs. 123 (95% CI: 84-180) mu g.180 min/L, respectively]. Free fatty acid nadir was reached earlier for VIT than for CON [34 (95% CI: 26-43) vs. 46 (95% CI: 31-57) min, respectively]. Glucose area under the curve, clearance rate and peak height, insulin time to reach the peak and clearance rate, and free fatty acid nadir did not differ between VIT and CON. The reduction in insulin release during a glucose tolerance test without changes in glucose clearance rate or area under the curve suggests that the vitamin supplement improved insulin sensitivity in feed-restricted lactating dairy cows.

About 1-Phenylurea, If you have any questions, you can contact Girard, CL; Vanacker, N; Beaudet, V; Duplessis, M; Lacasse, P or concate me.. Quality Control of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Recently I am researching about REALITY; SKILLS, Saw an article supported by the . Recommanded Product: 1-Phenylurea. Published in AMER ASSOC NEUROLOGICAL SURGEONS in ROLLING MEADOWS ,Authors: Lazaro, T; Srinivasan, VM; Rahman, M; Asthagiri, A; Barkhoudarian, G; Chambless, LB; Kan, P; Rao, G; Nahed, BV; Patel, AJ. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea

OBJECTIVE Neurosurgical education in the US has changed significantly as a consequence of the novel coronavirus (COVID-19) pandemic. Institutional social distancing requirements have resulted in many neurosurgical programs utilizing video conferencing for educational activities. However, it is unclear how or if these practices should continue after the pandemic. The objective of this study was to characterize virtual education in neurosurgery and understand how it should be utilized after COVID-19. METHODS A 24-question, 3-part online survey was administered anonymously to all 117 US neurosurgical residency programs from May 15, 2020, to June 15, 2020. Questions pertained to the current use of virtual conferencing, preferences over traditional conferences, and future inclinations. The Likert scale (1 = strongly disagree, 3 = neutral, 5 = strongly agree) was used. Comparisons were calculated using the Mann-Whitney U-test. Statistical significance was set at 0.05. RESULTS One-hundred eight responses were recorded. Overall, 38 respondents (35.2%) were attendings and 70 (64.8%) were trainees. Forty-one respondents (38.0%) indicated attending 5-6 conferences per week and 70 (64.8%) attend national virtual conferences. When considering different conference types, there was no overall preference (scores < 3) for virtual conferences over traditional conferences. In regard to future use, respondents strongly agreed that they would continue the practice at some capacity after the pandemic (median score 5). Overall, respondents agreed that virtual conferences would partially replace traditional conferences (median score 4), whereas they strongly disagreed with the complete replacement of traditional conferences (median score 1). The most common choices for the partial replacement of tradition conferences were case conferences (59/108, 55%) and board preparation (64/108, 59%). Lastly, there was a significant difference in scores for continued use of virtual conferencing in those who attend nationally sponsored conferences (median score 5, n = 70) and those who do not (median score 4, n = 38; U = 1762.50, z = 2.97, r = 0.29, p = 0.003). CONCLUSIONS Virtual conferences will likely remain an integral part of neurosurgical education after the COVID-19 pandemic has abated. Across the country, residents and faculty report a preference for continued use of virtual conferencing, especially virtual case conferences and board preparation. Some traditional conferences may even be replaced with virtual conferences, in particular those that are more didactic. Furthermore, nationally sponsored virtual conferences have a positive effect on the preferences for continued use of virtual conferences. https:// thejns.org/doi/abs/10.3171/2020.9.FOCUS20672 Recommanded Product: 1-Phenylurea. About 1-Phenylurea, If you have any questions, you can contact Lazaro, T; Srinivasan, VM; Rahman, M; Asthagiri, A; Barkhoudarian, G; Chambless, LB; Kan, P; Rao, G; Nahed, BV; Patel, AJ or concate me.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Application In Synthesis of 1-Phenylurea. In 2019.0 J CHEM THERMODYN published article about THERMODYNAMIC PROPERTIES; ALKYL DERIVATIVES; VAPOR-PRESSURES; STANDARD ENTHALPIES; COMBUSTION; THERMOCHEMISTRY; CRYSTALS; GAS in [Dorofeeva, Olga, V; Suchkova, Taisiya A.] Lomonosov Moscow State Univ, Fac Chem, 1-3 Leninskie Gory, Moscow 119991, Russia in 2019.0, Cited 38.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8.

The thermochemical network of 91 isodesmic and other balanced reactions was used to adjust simultaneously the enthalpies of formation of 14 urea compounds. The experimental enthalpies of formation of these compounds were treated as unknowns in the least-squares minimization of deviations between the theoretically predicted enthalpies of reaction and experimental values. A result of a least-squares fit confirms the accuracy of experimental enthalpies of formation of 8 ureas, whereas the experimental measurements for 6 urea compounds require re-examination. The gas-phase standard enthalpies of formation of 8 ureas were used as a consistent basis to obtain values for other 15 ureas through isodesmic reactions. To estimate the enthalpies of formation in crystalline state, the sublimation enthalpies were predicted using the molecular electrostatic potential model. (C) 2018 Elsevier Ltd.

Application In Synthesis of 1-Phenylurea. About 1-Phenylurea, If you have any questions, you can contact Dorofeeva, OV; Suchkova, TA or concate me.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Recently I am researching about EFFICIENT GENERATION; AM1-BCC MODEL; PROTEIN; DEGRADATION; ENANTIOMERS, Saw an article supported by the National Key R&D Program of China [2018YFA0901200]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31870087, 31670111]. Published in WILEY in HOBOKEN ,Authors: Huang, JW; Chen, D; Jiang, JD. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea. Quality Control of 1-Phenylurea

The (R)- and (S)-enantiomers of the chiral herbicide napropamide (NAP) show different biological activities and ecotoxicities. These two enantiomers behave differently in the environment due to enantioselective catabolism by microorganisms. However, the molecular mechanisms underlying this enantioselective catabolism remain largely unknown. In this study, the genes (snaH and snpd) involved in the catabolism of NAP were cloned from Sphingobium sp. B2, which was capable of catabolizing both NAP enantiomers. Compared with (R)-NAP, (S)-NAP was much more rapidly transformed by the amidase SnaH, which initially cleaved the amide bonds of (S)/(R)-NAP to form (S)/(R)-2-(1-naphthalenyloxy)-propanoic acid [(S)/(R)-NP] and diethylamine. The alpha-ketoglutarate-dependent dioxygenase Snpd, showing strict stereoselectivity for (S)-NP, further transformed (S)-NP to 1-naphthol and pyruvate. Molecular docking and site-directed mutagenesis analyses revealed that when the (S)-enantiomers of NAP and NP occupied the active sites, the distance between the ligand molecule and the coordination atom was shorter than that when the (R)-enantiomers occupied the active sites, which facilitated formation of the transition state complex. This study enhances our understanding of the preferential catabolism of the (S)-enantiomer of NAP on the molecular level.

About 1-Phenylurea, If you have any questions, you can contact Huang, JW; Chen, D; Jiang, JD or concate me.. Quality Control of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

In 2019.0 EUR J CANCER published article about BRAIN METASTASES; DOCETAXEL; PEMBROLIZUMAB; INHIBITORS in [Grossi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy; [Genova, Carlo] IRCCS Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy; [Crino, Lucio; Delmonte, Angelo] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy; [Turci, Daniele] Osped S Maria Delle Croci, Med Oncol Unit, Ravenna, Italy; [Signorelli, Diego] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy; [Passaro, Antonio] European Inst Oncol IRCCS, IEO, Div Thorac Oncol, Milan, Italy; [Parra, Hector Soto] Azienda Osped Univ AOU Policlin Vittorio Emanuele, Dept Oncol, Catania, Italy; [Catino, Annamaria] IRCCS Ist Tumori Giovanni Paolo II, Med Oncol Unit, Patol Torac, Bari, Italy; [Landi, Lorenza] AUSL Romagna, Dept Hematol Oncol, Ravenna, Italy; [Gelsomino, Francesco] AOU Policlin St Orsola Malpighi, Oncol Unit, Bologna, Italy; [Tiseo, Marcello] Univ Parma, Dept Med & Surg, Parma, Italy; [Tiseo, Marcello] Azienda Osped Univ Parma, Oncol Med, Parma, Italy; [Puppo, Gianfranco] Osped Macerata, Pulmonol Unit, Macerata, Italy; [Roila, Fausto] Osped S Maria Misericordia, Med Oncol Unit, Perugia, Italy; [Ricciardi, Serena] Azienda Osped San Camillo Forlanini, Pulm Oncol Unit, Rome, Italy; [Tonini, Giuseppe] Univ Campus Biomed, Dept Oncol, Rome, Italy; [Cognetti, Francesco] Univ Roma La Sapienza, Ist Nazl Tumori Regina Elena, Med Oncol Unit, Rome, Italy; [Toschi, Luca] IRCCS Ist Clin Humanitas, Dept Hematol Oncol, Rozzano, Italy; [Tassinari, Davide] AUSL Romagna, Oncol Unit, Rimini, Italy; [Scoppola, Alessandro] Ist Dermopat Immacolata, Dept Med Oncol, Rome, Italy; [Giannarelli, Diana] Ist Nazl Tumori Regina Elena, BIostat, Rome, Italy; [Cortesi, Enrico] Policlin Umberto 1, Oncol Unit, Rome, Italy in 2019.0, Cited 19.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. Formula: C7H8N2O

Background: Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced nonesmall cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression. Methods: Pretreated patients with advanced non-squamous NSCLC received nivolumab at 3 mg/kg every 2 weeks up to 24 months. Efficacy data (investigator-assessed tumour response, progression date and survival) and safety data were collected. Findings: 1588 patients were treated across 153 Italian centres. Overall response rate and disease control rate were 18% and 44%, respectively; median overall survival (OS) was 11.3 months (95% CI: 10.2-12.4). Elderly patients (>= 70 n = 522; >= 75 n = 232) achieved outcomes similar to the global study population; patients with CNS metastases (n = 409) had an OS of 8.6 months (95% CI: 6.4-10.8), and a 1-year OS rate of 43%. Nivolumab was administered beyond progression to 276 patients (26%), 57 of whom achieved subsequent disease control; the median OS of patients receiving nivolumab beyond progression was 16.2 months (95% CI: 14.0-18.4), while 1-year OS rate was 62%. Interpretation: To date, this is the largest clinical experience with nivolumab in a real-world setting. Our data support its use in clinical practice for pretreated non-squamous NSCLC, including patients with older age or CNS metastases. (C) 2019 Elsevier Ltd. All rights reserved.

Formula: C7H8N2O. About 1-Phenylurea, If you have any questions, you can contact Grossi, F; Genova, C; Crino, L; Delmonte, A; Turci, D; Signorelli, D; Passaro, A; Parra, HS; Catino, A; Landi, L; Gelsomino, F; Tiseo, M; Puppo, G; Roila, F; Ricciardi, S; Tonini, G; Cognetti, F; Toschi, L; Tassinari, D; Scoppola, A; Giannarelli, D; Cortesi, E or concate me.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem